Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

TSHA holding history

Taysha Gene Therapies, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

TSHA overviewAll 13F holders of TSHAFull Q2 2026 holdings

Shares (Q2 2026)
588,427
Value
$4.01M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of TSHA by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026588,427$4.01M<0.1%+70,729+13.7%AddedHolders
Q1 2026517,698$2.31M<0.1%+134,655+35.2%AddedHolders
Q4 2025383,043$2.11M<0.1%−256,313−40.1%ReducedHolders
Q3 2025639,356$2.09M<0.1%+378,117+144.7%AddedHolders
Q2 2025261,239$603.5K<0.1%−156,893−37.5%ReducedHolders
Q1 2025418,132$581.2K<0.1%−3,264−0.8%ReducedHolders
Q4 2024421,396$729.0K<0.1%+329,395+358.0%AddedHolders
Q3 202492,001$184.9K<0.1%+35,922+64.1%AddedHolders
Q2 202456,079$125.6K<0.1%−133,205−70.4%ReducedHolders
Q1 2024189,284$543.2K<0.1%+185,341+4,700.5%AddedHolders
Q4 20233,943$6.98K<0.1%+3,393+616.9%AddedHolders
Q3 2023550$1.74K<0.1%−7,359−93.0%ReducedHolders
Q2 20237,909$5.23K<0.1%+4,359+122.8%AddedHolders
Q1 20233,550$2.83K<0.1%−198,284−98.2%ReducedHolders
Q4 2022201,834$456.1K<0.1%+195,562+3,118.0%AddedHolders
Q3 20226,272$12.0K<0.1%−88,288−93.4%ReducedHolders
Q2 202294,560$352.0K<0.1%+26,580+39.1%AddedHolders
Q1 202267,980$443.0K<0.1%+16,944+33.2%AddedHolders
Q4 202151,036$594.0K<0.1%+17,653+52.9%AddedHolders
Q3 202133,383$622.0K<0.1%+28,083+529.9%AddedHolders
Q2 20215,300$112.0K<0.1%−30,911−85.4%ReducedHolders
Q1 202136,211$735.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.